Genmab — November 2017
-
This growth can be largely attributed to the expansion
of existing therapies such as the PD-1/PD-L1 inhibitors Opdivo and Keytruda and J&J’s Darzalex, as well as the launch of novel therapies, such as Sano /Regeron’s Dupixent in atopic dermatitis and Roche’s Ocrevus in multiple sclerosis. CAR-T therapies continue to generate interest in oncology although the recent safety issues have partially dampened any short term excitement. -
Optimist...pessimist...de store finanshuse(hedgefonde) styrer kursen. Hvis de synes den er mere værd stiger den og visa versa.
-
Hvis man er pessimist, så skal absolut ikke investere i aktier. Og slet ikke i biotek. Biotek handler om, om man tror på at diverse forsøg falder godt og heldigt ud til glæde for både patienter og investorer. Det er en slags lodseddel hvor man først kender de udtrukne numre når forsøget ( forsøgene ) er afsluttet ,og kan indkassere gevinsten eller tabet. Det er en lodseddel med ret lang løbetid.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind